Vertex Pharmaceuticals stock was heading for a double-digit gain this year until recent weeks. The company is approaching an important turning point -- one that could set the tone for revenue growth.

Vertex just won approval for a drug to treat one of the most common health problems -- pain. The biotech company is offering an option for patients and doctors who don’t want to go for controversial ...

Vertex Pharmaceuticals showed strong Q2 2023 earnings, with a 14% revenue increase driven by international sales of Trikafta/Kaftrio and U.S. growth. Management outlined growth initiatives in various ...

Google Cloud this week introduced Vertex AI Agent Builder, a new tool that consolidates Vertex AI Search and Conversation products, enhancing the developer's toolbox for generative AI agent ...